PC
NXTM

PointState Capital’s NxStage Medical Inc. NXTM Stock Holding History

PointState Capital’s Portfolio NXTM Stock Details NXTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-37,000
Closed -$1.03M – 158
2018
Q3 		$1.03M Sell
37,000
-35,300
-49% -$993K 0.01% 128
2018
Q2 		$2.02M Buy
+72,300
New +$1.94M 0.02% 138

Other funds holding NXTM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PointState Capital's NXTM Position: Q4 2018 in Review

PointState Capital sold out of NxStage Medical Inc. (NXTM) in Q4 2018, closing a stake of 37,000 shares — an estimated $1.03M sold.

PointState Capital first reported a position in NXTM in Q2 2018 and held it in 2 quarters. The position peaked at $2.02M in Q2 2018. 172 funds tracked by Wall St. Rank hold NXTM as of Q4 2018.

  • PointState Capital reported no remaining NxStage Medical Inc. position as of Q4 2018 after selling out during the quarter.
  • PointState Capital sold 37,000 NxStage Medical Inc. shares in Q4 2018, an estimated $1.03M.
  • PointState Capital first reported a position in NxStage Medical Inc. in Q2 2018 and held it in 2 quarters.
  • PointState Capital's NxStage Medical Inc. position peaked at $2.02M in Q2 2018.
  • 172 funds tracked by Wall St. Rank held NxStage Medical Inc. as of Q4 2018.

Based on PointState Capital's 13F filing for Q4 2018, filed 14 Feb 2019.